Basic Information
| RNALocate ID: | RLID:01001280 |
| RNA Symbol: | hsa-miR-19a-3p |
| Localization: | Nucleus |
RNA Information
| RNA Name: | hsa-miR-19a |
| RNA ID: | miRBase:MIMAT0000073 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 24918059 |
| Tissue/Cell Line: | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) |
| Method: | Microarray |
| Description: | Data are collected from supplementary Table S2. MiRNA reads in the subcellular fractions. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001278 | Cytoplasm | Colon cancer cells | 20864815 |
| RLID:01001279 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001281 | Nucleolus | Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001282 | Nucleus | Neural progenitor cells | 21363885 |
| RLID:11000710 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11000711 | Exosome | Renal cancer cells | 21670082 |
| RLID:11000712 | Exosome | Breast milk | 22211110 |
| RLID:11000713 | Exosome | Brain tissue | 23382797 |
| RLID:11000714 | Exosome | Plasma | 23663360 |
| RLID:11000715 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11000716 | Exosome | Human esophageal cancer cell line (EC9706) | 25184951 |
| RLID:11000717 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
| RLID:11000718 | Exosome | Cerebrospinal fluid | 25420022 |
| RLID:11000719 | Extracellular Vesicle | Liposarcoma cell lines (Lipo246|Lipo863|LPS141)|Preadipocytes | 28588009 |
| RLID:11000720 | Extracellular vesicle | HEK-293T cells | 22849433 |
| RLID:11000721 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11000722 | Microvesicle | Follicular fluid | 23666971 |
| RLID:11000723 | Microvesicle | Cerebrospinal fluid | 24797360 |
| RLID-D:11000010 | Exosome | B lymphoblastoid cells|Colon tissue|Endothelial cells|Lymphoma tissue | |
| RLID-D:11000272 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-19a-3p | Splenic marginal zone lymphoma | MNDR-E-MI-25274 |
| MNDR | hsa-miR-19a-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-25275 |
| MNDR | hsa-miR-19a-3p | Oral squamous cell carcinoma | MNDR-E-MI-25276 |
| MNDR | hsa-miR-19a-3p | Large cell neuroendocrine cancer | MNDR-E-MI-25277 |
| MNDR | hsa-miR-19a-3p | Follicular cleaved lymphoma | MNDR-E-MI-25278 |
| MNDR | hsa-miR-19a-3p | Medulloblastoma | MNDR-E-MI-25279 |
| MNDR | hsa-miR-19a-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-25280 |
| MNDR | hsa-miR-19a-3p | Spinocerebellar ataxia type 1 | MNDR-E-MI-25281 |
| MNDR | hsa-miR-19a-3p | Autism spectrum disorder | MNDR-E-MI-25282 |
| MNDR | hsa-miR-19a-3p | Lymphoma | MNDR-E-MI-25283 |
| MNDR | hsa-miR-19a-3p | Lymphoma non-hodgkin | MNDR-E-MI-25284 |
| MNDR | hsa-miR-19a-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-25285 |
| MNDR | hsa-miR-19a-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-25286 |
| MNDR | hsa-miR-19a-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-25287 |
| MNDR | hsa-miR-19a-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-25288 |
| MNDR | hsa-miR-19a-3p | Her2-receptor positive breast cancer | MNDR-E-MI-25289 |
| MNDR | hsa-miR-19a-3p | Breast cancer luminal | MNDR-E-MI-25290 |
| MNDR | hsa-miR-19a-3p | Niemann-pick disease type c | MNDR-E-MI-25291 |
| MNDR | hsa-miR-19a-3p | Lymphoblastic lymphoma | MNDR-E-MI-25292 |
| MNDR | hsa-miR-19a-3p | Thyroid carcinoma anaplastic | MNDR-E-MI-25293 |
| MNDR | hsa-miR-19a-3p | Prostate cancer | MNDR-E-MI-25294 |
| MNDR | hsa-miR-19a-3p | Gastric cancer | MNDR-E-MI-25295 |
| MNDR | hsa-miR-19a-3p | Gastric lymphoma | MNDR-E-MI-25296 |
| MNDR | hsa-miR-19a-3p | Alzheimer disease | MNDR-E-MI-25297 |
| MNDR | hsa-miR-19a-3p | Intracranial aneurysm | MNDR-E-MI-25298 |
| MNDR | hsa-miR-19a-3p | Bladder cancer | MNDR-E-MI-25299 |
| MNDR | hsa-miR-19a-3p | Esophageal carcinoma | MNDR-E-MI-25300 |
| MNDR | hsa-miR-19a-3p | Dysautonomia familial | MNDR-E-MI-25301 |
| MNDR | hsa-miR-19a-3p | Head and neck cancer | MNDR-E-MI-25302 |
| MNDR | hsa-miR-19a-3p | Leukemia | MNDR-E-MI-25303 |
| MNDR | hsa-miR-19a-3p | Huntington disease | MNDR-E-MI-25304 |
| MNDR | hsa-miR-19a-3p | Cardiovascular disease | MNDR-E-MI-25305 |
| MNDR | hsa-miR-19a-3p | Moyamoya disease | MNDR-E-MI-25306 |
| MNDR | hsa-miR-19a-3p | Lung cancer | MNDR-E-MI-25307 |
| MNDR | hsa-miR-19a-3p | Parkinson disease | MNDR-E-MI-25308 |
| MNDR | hsa-miR-19a-3p | Machado-joseph disease | MNDR-E-MI-25309 |
| MNDR | hsa-miR-19a-3p | Niemann-pick disease | MNDR-E-MI-25310 |
| MNDR | hsa-miR-19a-3p | Basal-like breast cancer | MNDR-E-MI-25311 |
| MNDR | hsa-miR-19a-3p | Congenital heart disease | MNDR-E-MI-25312 |
| MNDR | hsa-miR-19a-3p | Neuroendocrine neoplasia | MNDR-E-MI-25313 |
| MNDR | hsa-miR-19a-3p | Pancreatic cancer | MNDR-E-MI-25314 |
| MNDR | hsa-miR-19a-3p | Melanoma | MNDR-E-MI-25315 |
| MNDR | hsa-miR-19a-3p | Rectum adenocarcinoma | MNDR-E-MI-25316 |
| MNDR | hsa-miR-19a-3p | Nephroblastoma | MNDR-E-MI-25317 |
| MNDR | hsa-miR-19a-3p | Colon cancer | MNDR-E-MI-25318 |
| MNDR | hsa-miR-19a-3p | Colon adenocarcinoma | MNDR-E-MI-25319 |
| MNDR | hsa-miR-19a-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-25320 |
| MNDR | hsa-miR-19a-3p | Familial ovarian cancer | MNDR-E-MI-25321 |
| MNDR | hsa-miR-19a-3p | Prostate adenocarcinoma | MNDR-E-MI-25322 |
| MNDR | hsa-miR-19a-3p | Thyroid adenomas | MNDR-E-MI-25323 |
| MNDR | hsa-miR-19a-3p | Carcinoma ductal breast | MNDR-E-MI-25324 |
| MNDR | hsa-miR-19a-3p | Glioblastoma | MNDR-E-MI-25325 |
| MNDR | hsa-miR-19a-3p | Astrocytoma | MNDR-E-MI-25326 |
| MNDR | hsa-miR-19a-3p | Glioma | MNDR-E-MI-25327 |
| MNDR | hsa-miR-19a-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-25328 |
| MNDR | hsa-miR-19a-3p | Osteosarcoma | MNDR-E-MI-25329 |
| MNDR | hsa-miR-19a-3p | Liposarcoma | MNDR-E-MI-25330 |
| MNDR | hsa-miR-19a-3p | Cervical adenocarcinoma | MNDR-E-MI-25331 |
| MNDR | hsa-miR-19a-3p | Gastric adenocarcinoma | MNDR-E-MI-25332 |
| MNDR | hsa-miR-19a-3p | Cervical squamous cell carcinoma | MNDR-E-MI-25333 |
| MNDR | hsa-miR-19a-3p | Lung squamous cell carcinoma | MNDR-E-MI-25334 |
| MNDR | hsa-miR-19a-3p | Lung adenocarcinoma | MNDR-E-MI-25335 |
| MNDR | hsa-miR-19a-3p | Adrenocortical cancer | MNDR-E-MI-25336 |
| MNDR | hsa-miR-19a-3p | Thyroid carcinoma | MNDR-E-MI-25337 |
| MNDR | hsa-miR-19a-3p | Bladder urothelial carcinoma | MNDR-E-MI-25338 |
| MNDR | hsa-miR-19a-3p | Carcinoma renal cell | MNDR-E-MI-25339 |
| MNDR | hsa-miR-19a-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-25340 |
| MNDR | hsa-miR-19a-3p | Renal clear cell carcinoma | MNDR-E-MI-25341 |
| MNDR | hsa-miR-19a-3p | Cholangiocarcinoma | MNDR-E-MI-25342 |
| MNDR | hsa-miR-19a-3p | Esophageal cancer | MNDR-E-MI-25343 |
| MNDR | hsa-miR-19a-3p | Lung small cell carcinoma | MNDR-E-MI-25344 |
| MNDR | hsa-miR-19a-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-25345 |
| MNDR | hsa-miR-19a-3p | Notch-induced t-cell acute lymphoblastic leukemia | MNDR-E-MI-25346 |
| MNDR | hsa-miR-19a-3p | Cowden disease | MNDR-E-MI-25347 |
| MNDR | hsa-miR-19a-3p | Breast invasive carcinoma | MNDR-E-MI-25348 |
| MNDR | hsa-miR-19a-3p | Hepatocellular carcinoma | MNDR-E-MI-25349 |
| MNDR | hsa-miR-19a-3p | Familiar ovarian carcinoma | MNDR-E-MI-25350 |
| MNDR | hsa-miR-19a-3p | B-cell lymphoma | MNDR-E-MI-25351 |
| MNDR | hsa-miR-19a-3p | Rheumatoid arthritis | MNDR-E-MI-25352 |
| MNDR | hsa-miR-19a-3p | T-cell leukemia | MNDR-E-MI-25353 |
| MNDR | hsa-miR-19a-3p | Malignant pleural mesothelioma | MNDR-E-MI-25354 |
| MNDR | hsa-miR-19a-3p | Cervical carcinoma | MNDR-E-MI-25355 |
| MNDR | hsa-miR-19a-3p | Retinoblastoma | MNDR-E-MI-25356 |
| MNDR | hsa-miR-19a-3p | Neuroblastoma | MNDR-E-MI-25357 |
| MNDR | hsa-miR-19a-3p | Barrett's adenocarcinoma | MNDR-E-MI-25358 |
| MNDR | hsa-miR-19a-3p | Hodgkin lymphoma | MNDR-E-MI-25359 |
| MNDR | hsa-miR-19a-3p | Ulcerative colitis | MNDR-E-MI-25360 |
| MNDR | hsa-miR-19a-3p | Burkitt lymphoma | MNDR-E-MI-25361 |
| MNDR | hsa-miR-19a-3p | Lymphosarcoma | MNDR-E-MI-25362 |
| MNDR | hsa-miR-19a-3p | Crohn disease | MNDR-E-MI-25363 |
| MNDR | hsa-miR-19a-3p | Tonsil cancer | MNDR-E-MI-25364 |
| MNDR | hsa-miR-19a-3p | Psoriasis | MNDR-E-MI-25365 |
| MNDR | hsa-miR-19a-3p | Acute myelogenous leukemia | MNDR-E-MI-25366 |
| MNDR | hsa-miR-19a-3p | Colorectal cancer | MNDR-E-MI-25367 |
| MNDR | hsa-miR-19a-3p | Nasopharynx carcinoma | MNDR-E-MI-25368 |
| MNDR | hsa-miR-19a-3p | Acute myocardial infarction | MNDR-E-MI-25369 |
| MNDR | hsa-miR-19a-3p | Multiple myeloma | MNDR-E-MI-25370 |
| MNDR | hsa-miR-19a-3p | Esophageal squamous cell carcinoma | MNDR-E-MI-25371 |
| MNDR | hsa-miR-19a-3p | Ependymoma | MNDR-E-MI-25372 |
| MNDR | hsa-miR-19a-3p | Nasopharyngeal cancer | MNDR-E-MI-25373 |
| MNDR | hsa-miR-19a-3p | Prostatic neoplasms | MNDR-E-MI-25374 |
| MNDR | hsa-miR-19a-3p | Pseudorabies | MNDR-E-MI-25375 |
| MNDR | hsa-miR-19a-3p | Aids dementia complex | MNDR-E-MI-25376 |
| MNDR | hsa-miR-19a-3p | Epstein-barr virus infections | MNDR-E-MI-25377 |
| MNDR | hsa-miR-19a-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-25378 |
| MNDR | hsa-miR-19a-3p | Arsenic poisoning | MNDR-E-MI-25379 |
| MNDR | hsa-miR-19a-3p | Chronic pain | MNDR-E-MI-25380 |
| MNDR | hsa-miR-19a-3p | Stroke lacunar | MNDR-E-MI-25381 |
| MNDR | hsa-miR-19a-3p | Barrett's carcinogenesis | MNDR-E-MI-25382 |
| MNDR | hsa-miR-19a-3p | Breast cancer her3+ negative | MNDR-E-MI-25383 |
| MNDR | hsa-miR-19a-3p | Duke A | MNDR-E-MI-25384 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABCA1 | Homo sapiens | RR00022102 |
TOP